Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.
J Am Coll Cardiol. 2011 Dec 13;58(25):2675-82. doi: 10.1016/j.jacc.2011.08.054.
The aim of this study was to evaluate whether coronary heart disease (CHD)-susceptibility loci identified by genome-wide association studies of the general population also contribute to CHD in type 2 diabetes.
No study has examined the effects of these genetic variants on CHD in diabetic patients.
We genotyped 15 genetic markers of 12 loci in 3 studies of diabetic patients: the prospective Nurses' Health Study (309 CHD cases, and 544 control subjects) and Health Professional Follow-up Study (345 CHD cases, and 451 control subjects) and the cross-sectional Joslin Heart Study (422 CHD cases, and 435 control subjects).
Five single-nucleotide polymorphisms, rs4977574 (CDKN2A/2B), rs12526453 (PHACTR1), rs646776 (CELSR2-PSRC1-SORT1), rs2259816 (HNF1A), and rs11206510 (PCSK9) showed directionally consistent associations with CHD in the 3 studies, with combined odds ratios (ORs) ranging from 1.17 to 1.25 (p = 0.03 to 0.0002). None of the other single-nucleotide polymorphisms reached significance in individual or combined analyses. A genetic risk score (GRS) was created by combining the risk alleles of the 5 significantly associated loci. The OR of CHD/GRS unit was 1.19 (95% confidence interval: 1.13 to 1.26; p < 0.0001). Individuals with GRS ≥8 (19% of diabetic subjects) had almost a 2-fold increase in CHD risk (OR: 1.94, 95% confidence interval: 1.60 to 2.35) as compared with individuals with GRS ≤5 (30% of diabetic subjects). Prediction of CHD was significantly improved (p < 0.001) when the GRS was added to a model including clinical predictors in the combined samples.
Our results illustrate the consistency and differences in the determinants of genetic susceptibility to CHD in diabetic patients and the general populations.
本研究旨在评估通过全基因组关联研究确定的冠心病(CHD)易感基因座是否也与 2 型糖尿病患者的 CHD 相关。
尚无研究检测这些遗传变异对糖尿病患者 CHD 的影响。
我们对 3 项糖尿病患者研究中的 12 个基因座的 15 个遗传标记进行了基因分型:前瞻性护士健康研究(309 例 CHD 病例,544 例对照)、卫生专业人员随访研究(345 例 CHD 病例,451 例对照)和横断面Joslin 心脏研究(422 例 CHD 病例,435 例对照)。
在这 3 项研究中,5 个单核苷酸多态性(rs4977574[CDKN2A/2B]、rs12526453[PHACTR1]、rs646776[CELSR2-PSRC1-SORT1]、rs2259816[HNF1A]和 rs11206510[PCSK9])与 CHD 呈一致性方向关联,合并比值比(OR)范围为 1.17 至 1.25(p=0.03 至 0.0002)。其他单核苷酸多态性在个体或合并分析中均未达到显著性。通过将 5 个显著关联基因座的风险等位基因进行组合,创建了一个遗传风险评分(GRS)。CHD/GRS 单位的 OR 为 1.19(95%置信区间:1.13 至 1.26;p<0.0001)。与 GRS≤5(30%的糖尿病患者)的个体相比,GRS≥8(19%的糖尿病患者)的个体 CHD 风险增加近 2 倍(OR:1.94,95%置信区间:1.60 至 2.35)。在联合样本中,当 GRS 添加到包含临床预测因子的模型中时,CHD 的预测显著改善(p<0.001)。
本研究结果表明,糖尿病患者与普通人群 CHD 遗传易感性决定因素的一致性和差异。